Sichuan Biokin Pharmaceutical Co Ltd banner
S

Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506

Watchlist Manager
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Watchlist
Price: 272.74 CNY 0.64% Market Closed
Market Cap: ¥112.6B

P/E

-86.8
Current
38%
More Expensive
vs 3-y average of -62.7

Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.

P/E
-86.8
=
Market Cap
¥111.9B
/
Net Income
¥-1.3B

Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.

P/E
-86.8
=
Market Cap
¥111.9B
/
Net Income
¥-1.3B

Valuation Scenarios

Sichuan Biokin Pharmaceutical Co Ltd is trading above its industry average

If P/E returns to its Industry Average (25.5), the stock would be worth ¥-80.09 (129% downside from current price).

Statistics
Positive Scenarios
0/2
Maximum Downside
-134%
Maximum Upside
No Upside Scenarios
Average Downside
132%
Scenario P/E Value Implied Price Upside/Downside
Current Multiple -86.8 ¥272.74
0%
Industry Average 25.5 ¥-80.09
-129%
Country Average 29.6 ¥-93.05
-134%

Forward P/E
Today’s price vs future net income

Not enough data available to calculate forward P/E

Peer Comparison

All Countries
Close

Market Distribution

Lower than 100% of companies in China
Percentile
0th
Based on 5 557 companies
0th percentile
-86.8
Low
0 — 17.1
Typical Range
17.1 — 57.7
High
57.7 —
Distribution Statistics
China
Min 0
30th Percentile 17.1
Median 29.6
70th Percentile 57.7
Max 43 569.3

Sichuan Biokin Pharmaceutical Co Ltd
Glance View

Market Cap
112.6B CNY
Industry
Pharmaceuticals

Sichuan Biokin Pharmaceutical Co Ltd, nestled in the thriving economic landscape of China, is a dynamic force in the pharmaceutical industry. The company has carved a niche for itself by specializing in the production and commercialization of generic and proprietary drugs. Founded on the principles of innovation and accessibility, Biokin has dedicated its resources to the development of a wide range of pharmacological solutions that address both chronic and acute health conditions. Its state-of-the-art manufacturing facilities are complemented by rigorous research and development wings, where scientists and pharmacists collaborate meticulously to forge products that meet the stringent standards of efficacy and safety. At the heart of Sichuan Biokin's business model lies a commitment to affordability and quality, a combination that has enabled it to secure a significant share of the domestic pharmaceutical market. The company capitalizes on the economies of scale, leveraging its expansive production capabilities to reduce costs and enhance profit margins. By strategically aligning with healthcare providers and distributors, Biokin ensures its products efficiently reach hospitals, clinics, and pharmacies across the nation. This extensive distribution network not only enhances accessibility for patients but also cements Biokin’s reputation as a reliable pharmaceutical partner. Meanwhile, its growing portfolio of consumer healthcare products, alongside ongoing investments in biosimilars and more complex drug formulations, positions Biokin to thrive in the ever-evolving global healthcare arena.

Intrinsic Value
30.63 CNY
Overvaluation 89%
Intrinsic Value
Price ¥272.74
S
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett